LIQ861

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) […]

maralixibat

maralixibat Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome FOSTER CITY, Calif.–(BUSINESS WIRE)–Mar. 29, 2021– Mirum Pharmaceuticals, […]